Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience

Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patientswith Parkinson’s disease (PD).Materials and methods: We had telephone calls with 54 patients from 11 neurology centers who were on LCIG treatment, and 44patients or their caregivers were included in an eight-item survey between September 2015 and June 2016. The reliability and validity ofthe survey were evaluated with intraclass correlation coefficients for every question separately.Results: Average age of the patients were 63.48 and the duration of PD was 12.79 years. Average LCIG treatment period was 15.63months. Percentages of the patients who reported they were ‘better’ after LCIG treatment were as follows: 80% for time spent off, 55% fordyskinesia, 65% for tremor, 85% for gait disorder, 50% for pain, 50% for sleep disorders, 42.5% for depression, 32.5% for incontinence,and 70% for activities of daily living. Cronbach’s alpha was 0.795 and the intraclass correlation coefficient was reliable for the items.Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIGtreatment in many aspects of the disease.

PDF

___

1. Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurology 2006; 5: 525-535.
2. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009; 373: 2055-2066.
3. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 2010; 24: 119-129.
4. Tetrud JW. Balancing short-term symptom control and longterm functional outcomes in patients with Parkinson’s disease. CNS Spectrums 2007; 12: 275-286. 5. Stocchi F, Tagliati M, Olanow CW. Treatment of levodopainduced motor complications. Movement Disorders 2008; 23: 559-612.
6. Chang FCF, Kwan V, van der Poorten D, Mahant N, Wolfe N et al. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease. Journal of Clinical Neuroscience 2016; 25: 41-45.
7. Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Movement Disorders 2015; 30: 500-509.
8. Buongiorno M, Antonelli F, Cámara A, Puente V, De Fabregues- Nebot O et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. Parkinsonism & Related Disorders 2015; 21: 871-876.
9. Virhammar J, Nyholm D. Levodopa carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence experience. Therapeutic Advances in Neurological Disorders 2017; 10: 171-187.
10. Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A et al. EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Movement Disorders 2015; 30: 510-516.
11. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye G et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders 2009; 24: 1468-1474.
12. Melgari J, Salomone G, Di Biase L, Marano M, Scrascia F et al. Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: management in clinical practice. Parkinsonism & Related Disorders 20015; 21: 327-328.
13. Slevin J, Fernandez HH, Zadikoff C, Hall C, Eaton S et al. Long-term safety and maintenance of efficacy of levodopacarbidopa intestinal gel: an open-label extension of the double blind pivotal study in advanced Parkinson’s disease patients. Journal of Parkinson’s Disease 2015; 5: 165-174.
14. Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA et al. Levodopa carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism & Related Disorders 2013; 19: 339-345.
15. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology 2014; 13: 141-149.
16. Băjenaru O, Ene A, Popescu BO, Szasz JA, Sabau M et al. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience. Journal of Neural Transmission 2016; 123: 407-414.
17. Cáceres-Redondo MT, Carrillo F, Lama MJ, Huertas- Fernández I, Vargas-González L et al. Long-term levodopa/ carbidopa intestinal gel in advanced Parkinson’s disease. Journal of Neurology 2014; 261: 561-569.
18. Wirdefeldt K, Odin P, Nyholm D. Levodopa carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS Drugs 2016; 30: 381-404.
19. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and nonmotor symptoms and safety of levodopa–carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism & Related Disorders 2015; 21: 231- 235.
20. Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D et al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. Journal of Neural Transmission 2014; 121: 633-642.
21. Bohlega S, Abou Al-Shaar H, Alkhairallah T, Al-Ajlan F, Hasan N et al. Levodopa–carbidopa intestinal gel infusion therapy in advanced Parkinson’s disease: Single middle eastern center experience. European Neurology 2015; 74: 227-236.